B-Cell Lymphoma
125
23
30
48
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
20 trials with published results (16%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.2%
14 terminated out of 125 trials
77.4%
-9.1% vs benchmark
3%
4 trials in Phase 3/4
42%
20 of 48 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 48 completed trials
Clinical Trials (125)
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase I Study of FXS0683 in the Treatment of Blood Tumors
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma